23 February 2012 Business
Industry news, March 2012
The US Food and Drug Administration has given the nod to anti-obesity drug lorcaserin. The drug, which has been developed by US-based Arena Pharmaceuticals, in conjunction with Japan’s Eisai, is the first obesity prescription medicine approved for 13 years.
The approval comes after a lengthy review by the FDA over concerns that the drug might cause damage to heart valves. The drug, which will be marketed as Belviq, will be used to treat people with a body mass index of 30 or greater. In trials, the average weight loss among volunteers who combined the drug with exercise and dieting was between 3% and 3.7% greater than a placebo. The drug works by activating the serotonin 2C receptor in the brain which is thought to increase feelings of satiety.
13 May 2013 Research
'Liquid fingerprinting' can 'taste' the difference between red wines, mineral waters and vodkas
14 May 2013 News and Analysis
New legislation proposes the appointment of a public champion for research